US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>IPO Launch: SpyGlass Pharma (SGP US) filed for a 9.375 million-share IPO at $15–$17, aiming to debut on February 6th with a $467–$534 million market cap. </li>
<li>Lead Product &amp; Trials: Its BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery; two Phase 3 trials are underway.Use of Proceeds &amp;</li>
<li>IPO proceeds will fund trials, R&amp;D, and potential commercial launch; company backed by top-tier investors including NEA, RA Capital, and Vensana Capital.</li>
</ul>


IPO Launch: SpyGlass Pharma (SGP US) filed for a 9.375 million-share IPO at $15–$17, aiming to debut on February 6th with a $467–$534 million market cap. 
Lead Product &amp; Trials: Its BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery; two Phase 3 trials are underway.Use of Proceeds &amp;
IPO proceeds will fund trials, R&amp;D, and potential commercial launch; company backed by top-tier investors including NEA, RA Capital, and Vensana Capital.


SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

<ul>
<li>SpyGlass Pharma (SGP US) filed for an IPO on January 16th, targeting a potential February debut to fund its glaucoma drug-delivery platform.</li>
<li>The BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery, addressing adherence issues in a $13B U.S. glaucoma market.</li>
<li>Privately backed by top-tier venture investors, SpyGlass has raised ~$200M, holds an exclusive University of Colorado license, and is advancing two Phase 3 registrational trials.</li>
</ul>


SpyGlass Pharma (SGP US) filed for an IPO on January 16th, targeting a potential February debut to fund its glaucoma drug-delivery platform.
The BIM-IOL System delivers three years of bimatoprost via drug-eluting intraocular lenses during cataract surgery, addressing adherence issues in a $13B U.S. glaucoma market.
Privately backed by top-tier venture investors, SpyGlass has raised ~$200M, holds an exclusive University of Colorado license, and is advancing two Phase 3 registrational trials.


SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care

<ul>
<li>Avalyn Pharma Inc. priced above expectations and surged 44% at open, closing up ~64% in a strong first-day performance.</li>
<li>Upsized deal and multiple-times oversubscribed book reflect high-quality institutional demand and strong biotech sector momentum.</li>
<li>Marks a positive inflection for pulmonary fibrosis IPOs after prior underperformance, signaling improving investor sentiment in the subsector.</li>
</ul>


Avalyn Pharma Inc. priced above expectations and surged 44% at open, closing up ~64% in a strong first-day performance.
Upsized deal and multiple-times oversubscribed book reflect high-quality institutional demand and strong biotech sector momentum.
Marks a positive inflection for pulmonary fibrosis IPOs after prior underperformance, signaling improving investor sentiment in the subsector.


Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

United States

Spyglass Pharma, Inc. operates as an ophthalmic biotechnology company. The company provides drug delivery platform, lasting treatment, and routine ophthalmic surgery. Spyglass Pharma serves glaucoma patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SpyGlass Pharma (SGP US)

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.

IPO Boutique

SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care

SpyGlass Pharma files for IPO to fund innovative glaucoma drug-delivery platform, targeting $13B U.S. market with BIM-IOL System.

IPO Boutique

Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

SpyGlass Pharma, Inc. (SGP): Glaucoma Care Biotech Sets Terms for IPO, Joins Heavy Issuance Week

​SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.

IPO Boutique

SpyGlass Pharma, Inc. (SGP): Peeking at the IPO Prospectus Of Company Transforming Glaucoma Care

​SpyGlass Pharma files for IPO to fund innovative glaucoma drug-delivery platform, targeting $13B U.S. market with BIM-IOL System.

IPO Boutique

Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO

​Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...

IPO Boutique

SpyGlass Pharma files for IPO to raise funds for their BIM-IOL System, aiming for a market cap of $467-$534 million with backing from top investors.

SpyGlass Pharma files for IPO to fund innovative glaucoma drug-delivery platform, targeting $13B U.S. market with BIM-IOL System.

Avalyn Pharma Inc. IPO exceeds expectations, surges 64% in strong debut, reflecting high institutional demand and improving investor sentiment in...